SGLT-2 Inhibitors and Cardiovascular Risk-Reference-Cited by-同舟云学术

SGLT-2 Inhibitors and Cardiovascular Risk

Published:2018-06 Issue:22 Volume:71 Page:2497-2506
ISSN:0735-1097
Container-title:Journal of the American College of Cardiology
language:en
Short-container-title:Journal of the American College of Cardiology

Author:

Cavender Matthew A.,Norhammar Anna,Birkeland Kåre I.,Jørgensen Marit Eika,Wilding John P.,Khunti Kamlesh,Fu Alex Z.,Bodegård Johan,Blak Betina T.,Wittbrodt Eric,Thuresson Marcus,Fenici Peter,Hammar Niklas,Kosiborod Mikhail,Kosiborod Mikhail,Cavender Matthew A.,Fu Alex Z.,Wilding John P.,Khunti Kamlesh,Norhammar Anna,Birkeland Kåre I,Jørgensen Marit Eika,Holl Reinhard W.,Hammar Niklas,Fenici Peter,Chen Hungta,Bodegård Johan,Blak Betina T.,Wittbrodt Eric T.,Scheerer Markus F,Surmont Filip,Nahrebne Kyle,Gulseth Hanne Løvdal,Carstensen Bendix,Thuresson Marcus,Bollow Esther,García Rodríguez Luis Alberto,Cea Soriano Lucia,Cantero Oscar Fernándex,Thiel Ellen,Murphy Brian

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference28 articles.

1. Association of cardiometabolic multimorbidity with mortality;Di Angelantonio;JAMA,2015

2. Impact of diabetes mellitus on hospitalization for heart failure, cardiovascular events, and death: outcomes at 4 years from the Reduction of Atherothrombosis for Continued Health (REACH) registry;Cavender;Circulation,2015

3. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes;Zinman;N Engl J Med,2015

4. Optimizing the analysis strategy for the CANVAS program: a prespecified plan for the integrated analyses of the CANVAS and CANVAS-R trials;Neal;Diabetes Obes Metab,2017

5. Canagliflozin and cardiovascular and renal events in type 2 diabetes;Neal;N Engl J Med,2017

Cited by 106 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sodium–glucose cotransporter 2 inhibitors and the cancer patient: from diabetes to cardioprotection and beyond;Basic Research in Cardiology;2024-06-27

2. Dapagliflozin-Saxagliptin Combination - The Quest for Optimal Glycemic Control With Cardio-Renal Protection in Type 2 Diabetes Mellitus: An Expert Consensus in Indian Settings;Journal of Endocrinology and Metabolism;2024-06

3. Hypoglycemic Drugs in Patients with Diabetes Mellitus and Heart Failure: A Narrative Review;Medicina;2024-05-30

4. The Acute Coronary Syndrome Risk in Medically Managed Subjects with Type 2 Diabetes Mellitus: Is the ASCVD Risk Score Failing Here?;Journal of the ASEAN Federation of Endocrine Societies;2024-05-25

5. Comparative effectiveness of second line oral antidiabetic treatments among people with type 2 diabetes mellitus: emulation of a target trial using routinely collected health data;BMJ;2024-05-08